Tuzi, Alessandro, et al. “Epirubicin and Docetaxel As Neoadjuvant Treatment of Hormone Receptor Positive, HER-2 Negative Breast Cancer: Results from Two Successive Phase II Studies”. Radiology and Oncology, vol. 47, no. 1, Apr. 2013, https://radioloncol.com/index.php/ro/article/view/728.